Showing 17,401 - 17,420 results of 28,274 for search '(( 50 ((na decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 12 men decrease ))', query time: 0.93s Refine Results
  1. 17401
  2. 17402
  3. 17403
  4. 17404
  5. 17405
  6. 17406

    Characteristics of Physician Outflow from Disaster Areas following the Great East Japan Earthquake by Saori Kashima (126020)

    Published 2017
    “…<div><p>Objective</p><p>The shortage of physicians after a major disaster is a crucial issue. We aimed to evaluate the characteristics of physicians who left affected areas following the accident at Fukushima Daiichi Nuclear Power Plant caused by the Great East Japan Earthquake on March 11, 2011.…”
  7. 17407
  8. 17408
  9. 17409
  10. 17410
  11. 17411
  12. 17412
  13. 17413
  14. 17414

    Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE) by Ibrahima Gaye (8462562)

    Published 2025
    “…Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). …”
  15. 17415
  16. 17416
  17. 17417
  18. 17418

    Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) reverse methacholine airway hyperresponsiveness in rats by Mounira Tlili (12847046)

    Published 2022
    “…PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.…”
  19. 17419
  20. 17420

    Effect of mini-dose ready-to-use liquid glucagon on preventing exercise-associated hypoglycemia in adults with type 1 diabetes by Ronnie Aronson (3705877)

    Published 2023
    “…</p> <p>Research Design and Methods</p> <p>Individuals initially participated in the in-clinic training phase for which they were randomized to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. …”